Akebia Therapeutics Inc (STU:AX9)
€ 1.008 0.025 (2.54%) Market Cap: 213.24 Mil Enterprise Value: 214.06 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Akebia Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 05:30PM GMT
Eric William Joseph
JP Morgan Chase & Co, Research Division - VP & Senior Analyst

All right. Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan.

And our next presenting company is Akebia Therapeutics. It's my pleasure to welcome CEO, John Butler, to tell us a little bit about the company.

Just as a reminder, the breakout Q&A for this session will be in the Olympic Room.

With that, John?

John P. Butler
Akebia Therapeutics, Inc. - CEO, President & Director

Eric, thanks so much. Thanks for the opportunity to present this morning.

I just want to remind everyone that I'm going to be making forward-looking statements. So please refer to our SEC filings for more information.

It is very exciting to have the opportunity to talk to you about Akebia today. We are a company with a clear purpose and a clear strategic focus, and that's to better the life of each person impacted by kidney disease.

This is a huge public health issue. There are 37 million Americans who are impacted by

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot